Clover Biopharmaceuticals, Ltd. - B: insider trades · Hong Kong · HKEX HKEX:clover-biopharmaceuticals-ltd-b HK HK · HKEX Mcap 312M€ Healthcare
Discover the full insider trade history of Clover Biopharmaceuticals, Ltd. - B, a listed issuer based in Hong Kong. Shares are listed on HK HK, under the oversight of HKEX. Operating in the Healthcare sector, Clover Biopharmaceuticals, Ltd. - B has recorded 26 insider filings. Market capitalisation: €312.4m. The latest transaction was reported on 24 April 2026 — Sale. Among the most active insiders: Liang Peng. Every trade is accessible without an account.
€429,331
6 ops.
Sell Volume
Financial data FY ended December 2024 · cache
Income statement
Revenue 38.4 M€
Gross profit 21.6 M€ 56% margin
Net income −903.4 M€ -2351.5% margin
Balance sheet & cash
Market cap 312.4 M€
Total debt 89.6 M€
Free Cash Flow −290.1 M€
Last declaration on 24 April 2026
Declarations 26 total
Executives ● Sale13 HKEX
€206,156 600,000 shares @ €0.3436 0.066% mcap 48.0% of flow
HKEX:DA20260424E00084 · 21 Apr 2026
Executives ● Sale8 HKEX
€101,199 300,000 shares @ €0.3373 0.032% mcap 23.6% of flow
HKEX:DA20260417E00037 · 15 Apr 2026
Executives ● Other2 HKEX
49,000 shares
HKEX:DA20260409E00126 · 2 Apr 2026
Executives ● Other2 HKEX
2,412,875 shares
HKEX:DA20260409E00096 · 2 Apr 2026
Executives ● Other2 HKEX
49,000 shares
HKEX:DA20260409E00105 · 2 Apr 2026
Executives ● Other2 HKEX
49,000 shares
HKEX:DA20260409E00113 · 2 Apr 2026
Executives ● Other2 HKEX
49,000 shares
HKEX:DA20260409E00086 · 2 Apr 2026
Executives ● Purchase2 HKEX
383,000 shares
HKEX:DA20260409E00099 · 2 Apr 2026
Ideal exit: 28 Dec 2026 (T+270) Executives ● Sale2 HKEX
1,086,000 shares
HKEX:DA20260409E00098 · 2 Apr 2026
Executives ● Purchase2 HKEX
1,326,875 shares
HKEX:DA20260409E00100 · 2 Apr 2026
Ideal exit: 28 Dec 2026 (T+270) Executives ● Sale2 HKEX
189,500 shares
HKEX:DA20260409E00094 · 2 Apr 2026
Executives ● Other2 HKEX
572,500 shares
HKEX:DA20260409E00092 · 2 Apr 2026
Executives ● Other2 HKEX
49,000 shares
HKEX:DA20260409E00117 · 2 Apr 2026
Executives ● Other2 HKEX
49,000 shares
HKEX:DA20260409E00120 · 2 Apr 2026
Executives ● Purchase2 HKEX
9,840 shares
HKEX:DA20260403E00017 · 31 Mar 2026
Ideal exit: 26 Dec 2026 (T+270) Executives ● Sale2 HKEX
500 shares
HKEX:DA20260403E00016 · 31 Mar 2026
Executives ● Other2 HKEX
10,340 shares
HKEX:DA20260403E00015 · 31 Mar 2026
Executives ● Purchase2 HKEX
340,000 shares
HKEX:DA20260401E00056 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
340,000 shares
HKEX:DA20260401E00045 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
340,000 shares
HKEX:DA20260401E00054 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
6,577,500 shares
HKEX:DA20260401E00050 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
1,145,000 shares
HKEX:DA20260401E00048 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
340,000 shares
HKEX:DA20260401E00058 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
340,000 shares
HKEX:DA20260401E00053 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) Executives ● Purchase2 HKEX
340,000 shares
HKEX:DA20260401E00052 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270) 25 of 26 declarations
Load more (1 remaining) About Clover Biopharmaceuticals, Ltd. - B Clover Biopharmaceuticals, Ltd. is a biopharmaceutical company focused on developing vaccines and therapies for infectious diseases. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.